Roche to acquire 89bio in $3.5B deal
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The lab will facilitate the development of herbal and natural-based solutions
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated